Advanced search
Publication Cover
Journal of Inflammation Research Volume 16, 2023 - Issue
Submit an article Journal homepage
190
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Tofacitinib for the Treatment of Psoriasiform Dermatitis Caused by IL-17 Inhibitors: A Case Report

Nan LuoDepartment of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-5163-3682View further author information
ORCID Icon,
Lingyuan ZhongDepartment of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of ChinaView further author information
,
Nana LuoDepartment of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-4141-6577View further author information
ORCID Icon,
Qiuyue WangDepartment of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of ChinaView further author information
,
Tianhao LiDepartment of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of ChinaView further author information
&
Pingsheng HaoDepartment of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-0376-6269View further author information
ORCID Icon
Pages 2167-2172 | Received 19 Mar 2023, Accepted 10 May 2023, Published online: 19 May 2023

References

  • Berger A. Science commentary: Th1 and Th2 responses: what are they? BMJ. 2000;321(7258):424. doi:10.1136/bmj.321.7258.424
  • Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71–87. doi:10.1136/annrheumdis-2020-218398
  • Cohen JN, Bowman S, Laszik ZG, North JP. Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: a retrospective study of T helper type 2 and 17 subsets, interleukin 36, and β-defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor α inhibitor-associated dermatitis. J Am Acad Dermatol. 2020;82(2):430–439. doi:10.1016/j.jaad.2019.08.023
  • Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 2006;24(6):274–280. doi:10.1016/j.tibtech.2006.04.001
  • Bose R, Beecker J. Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: a case report. SAGE Open Med Case Rep. 2020;8:2050313x20904561. doi:10.1177/2050313X20904561
  • Mendes Roncada EV, Brambilla VR, Freitas Filitto B, Genta MP, Morgado de Abreu MAM. Atopic dermatitis as a paradoxical effect of secukinumab for the treatment of psoriasis. Case Rep Dermatol. 2021;13(2):336–339. doi:10.1159/000513467
  • Parker JJ, Sugarman JL, Silverberg NB, et al. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children. Pediatr Dermatol. 2021;38(6):1500–1505. doi:10.1111/pde.14820
  • Ishiuji Y, Umezawa Y, Asahina A, et al. Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: report of two cases. J Dermatol. 2018;45(6):732–734. doi:10.1111/1346-8138.14295
  • Chiu HY, Wang TS, Chang CY, Tsai TF. The effectiveness and safety of Adalimumab in the treatment of non‐reimbursed patients with mild‐to‐moderate psoriasis. J Eur Acad Dermatol Venereol. 2012;26(8):991–998. doi:10.1111/j.1468-3083.2011.04199.x
  • Chang SH, Reynolds JM, Pappu BP, Chen G, Martinez GJ, Dong C. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity. 2011;35(4):611–621. doi:10.1016/j.immuni.2011.09.010
  • Joulia R, Guerrero-Fonseca IM, Girbl T, et al. Neutrophil breaching of the blood vessel pericyte layer during diapedesis requires mast cell-derived IL-17A. Nat Commun. 2022;13(1):7029. doi:10.1038/s41467-022-34695-7
  • Liu R, Lauridsen HM, Amezquita RA, et al. IL-17 promotes neutrophil-mediated immunity by activating microvascular pericytes and not endothelium. J Immunol. 2016;197(6):2400–2408. doi:10.4049/jimmunol.1600138
  • O’Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28(4):477–487. doi:10.1016/j.immuni.2008.03.002
  • Palmroth M, Kuuliala K, Peltomaa R, et al. Tofacitinib suppresses several JAK-STAT pathways in rheumatoid arthritis in vivo and baseline signaling profile associates with treatment response. Front Immunol. 2021;12:738481. doi:10.3389/fimmu.2021.738481
  • Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol. 2010;28:445–489. doi:10.1146/annurev-immunol-030409-101212
  • Koga T, Sato T, Umeda M, et al. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: impact of this JAK inhibitor on T-cell differentiation. Clin Immunol. 2016;173:147–148. doi:10.1016/j.clim.2016.10.003

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.